Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: October 19th 2024 | Updated: October 22nd 2024
Revolutionizing CLL Care With Targeted and Cellular Therapies
Published: October 19th 2024 | Updated: October 22nd 2024
Zakharia Evaluates Available Combination Options for Non–Clear Cell RCC
Published: January 9th 2024 | Updated: October 22nd 2024
FDA OKs NDA for SH-105 in Breast and Ovarian Cancer
Published: April 13th 2021 | Updated: October 22nd 2024
FDA Accelerates Approval of Sacituzumab Govitecan in Locally Advanced or Metastatic UC
Published: June 9th 2023 | Updated: October 22nd 2024
Choosing Biomarker Assays After Metastatic Relapse of ER+, HER- Breast Cancer